Gisadenafil

CAS No. 334826-98-1

Gisadenafil( UK-369003 )

Catalog No. M26695 CAS No. 334826-98-1

Gisadenafil is a selective inhibitor of phosphodiesterase 5 (PDE5) with an IC50 of 3.6 nM and prevents degradation of cGMP.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 393 Get Quote
10MG 581 Get Quote
25MG 888 Get Quote
50MG 1242 Get Quote
100MG 1674 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Gisadenafil
  • Note
    Research use only, not for human use.
  • Brief Description
    Gisadenafil is a selective inhibitor of phosphodiesterase 5 (PDE5) with an IC50 of 3.6 nM and prevents degradation of cGMP.
  • Description
    Gisadenafil is a selective inhibitor of phosphodiesterase 5 (PDE5) with an IC50 of 3.6 nM and prevents degradation of cGMP.(In Vitro):In COS-7 cells, the IC50 of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in selectivity.(In Vivo):In male Tat-transgenic mice, Gisadenafil (2 mg/kg; i.p.) restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels. Gisadenafil largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline).
  • In Vitro
    Since some PDE5 inhibitors can also interact with PDE1 isotypes found within the cerebral vasculature, the specificity of Gisadenafil for PDE5 is confirmed. This is directly tested with recombinant PDE5A and PDE1A overexpressed in COS-7 cells. The IC50 of Gisadenafil for PDE5A is 3.6 nM. In contrast, the IC50 of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in specificity.
  • In Vivo
    Gisadenafil (2 mg/kg; intraperitoneal injection; for 2 hours; male Tat-transgenic mice) treatment largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Gisadenafil also restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels. Animal Model:Male Tat-transgenic (Tat-tg) mice (8 weeks old) exposed to hypercapnia Dosage:2 mg/kg Administration:Intraperitoneal injection; for 2 hours Result:Largely restored the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Also restored the dilation of small (<25 μm) arterioles following hypercapnia.
  • Synonyms
    UK-369003
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    Estrogen Receptor/ERR| Human Endogenous Metabolite
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    334826-98-1
  • Formula Weight
    519.62
  • Molecular Formula
    C23H33N7O5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCOc1ncc(cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1)S(=O)(=O)N1CCN(CC)CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Choi HJ, et al. 4-Hydroxyestrone, an Endogenous Estrogen Metabolite, Can Strongly Protect Neuronal Cells Against Oxidative Damage. Sci Rep. 2020 Apr 29;10(1):7283.
molnova catalog
related products
  • BAY 2666605

    BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.

  • MY-5445

    MY-5445 is a specific inhibitor of phosphodiesterase type 5 (PDE5). MY-5445 selectively inhibits cGMP PDE (Ki:1.3 μM).

  • ML-030

    ML-030 is a potent and selective inhibitor of PDE4(PDE4A, PDE4A1, PDE4B1, PDE4B2, PDE4C1,and PDE4D2 with IC50 of 6.7 nM, 12.9 nM, 48.2 nM, 37.2 nM, 452 nM and 49.2 nM, respectively)